Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | October 8, 2008 | ||||
Last Updated Date | July 1, 2011 | ||||
Start Date ICMJE | September 2008 | ||||
Primary Completion Date | November 2009 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Safety [ Time Frame: At completion of first 6 patients ] [ Designated as safety issue: Yes ] Frequency of severe (grade 3) toxicities |
||||
Original Primary Outcome Measures ICMJE |
|
||||
Change History | Complete list of historical versions of study NCT00769990 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
|
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | ||||
Official Title ICMJE | Phase I-II Trial of Genistein in Subjects Receiving Palliative External Beam Radiation Therapy for Osseous Metastases: A Study of Palliation of Symptoms and Quality of Life | ||||
Brief Summary | RATIONALE: Genistein may increase the effectiveness of radiation therapy in treating pain caused by bone metastases. PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in treating patients undergoing external-beam radiation therapy for pain caused by bone metastases. |
||||
Detailed Description | OBJECTIVES:
OUTLINE: This is a multicenter study. Patients undergo external beam radiotherapy once daily on days 1-10. Patients also receive oral genistein once daily on days 1-60. Patients complete pain and quality-of-life questionnaires periodically. After completion of study therapy, patients are followed at 30 days. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 1 Phase 2 |
||||
Study Design ICMJE | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arm (s) | Experimental: Genistein
Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
Interventions:
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Withdrawn | ||||
Enrollment ICMJE | 0 | ||||
Completion Date | April 2010 | ||||
Primary Completion Date | November 2009 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 18 Years and older | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT00769990 | ||||
Other Study ID Numbers ICMJE | 2008LS035, UMN-0803M29541 | ||||
Has Data Monitoring Committee | Yes | ||||
Responsible Party | Shalamar Sibley, Masonic Cancer Center at University of Minnesota | ||||
Study Sponsor ICMJE | Masonic Cancer Center, University of Minnesota | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Masonic Cancer Center, University of Minnesota | ||||
Verification Date | July 2011 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |